No Data
No Data
CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Maintains Target Price $93
Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (MCRB), BioMarin Pharmaceutical (BMRN) and Exact Sciences (EXAS)
Goldman's 'Goldilocks' Mid-cap Picks That Trade at Reasonable Valuations
Don't Miss These Investor Days in September. How to Trade Them with Options
Unusual Options Activity: OVV, KKR and Others Attract Market Bets, OVV V/OI Ratio Reaches 190.3
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
No Data
No Data